◎ Sugi Atlas

Atlas / Gene / GDPD3

GDPD3

gene
On this page

Also known as MGC4171

Summary

GDPD3 (glycerophosphodiester phosphodiesterase domain containing 3, HGNC:28638) is a protein-coding gene on chromosome 16p11.2, encoding Lysophospholipase D GDPD3 (Q7L5L3). Hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the corresponding amines.

Enables phosphoric diester hydrolase activity. Involved in N-acylethanolamine metabolic process. Located in endoplasmic reticulum.

Source: NCBI Gene 79153 — RefSeq curated summary.

At a glance

  • GWAS associations: 6
  • Clinical variants (ClinVar): 61 total — 1 pathogenic, 1 likely-pathogenic
  • MANE Select transcript: NM_024307

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:28638
Approved symbolGDPD3
Nameglycerophosphodiester phosphodiesterase domain containing 3
Location16p11.2
Locus typegene with protein product
StatusApproved
AliasesMGC4171
Ensembl geneENSG00000102886
Ensembl biotypeprotein_coding
OMIM616318
Entrez79153

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 retained_intron, 2 protein_coding, 1 nonsense_mediated_decay

ENST00000360688, ENST00000406256, ENST00000565704, ENST00000566434, ENST00000566613

RefSeq mRNA: 1 — MANE Select: NM_024307 NM_024307

CCDS: CCDS10671

Canonical transcript exons

ENST00000406256 — 10 exons

ExonStartEnd
ENSE000013496713011265830112793
ENSE000015209383011302230113064
ENSE000016921713011334030113537
ENSE000034812793010481030105009
ENSE000034990593011138830111521
ENSE000035320313010821330108264
ENSE000035865183011213230112221
ENSE000035874163011230630112424
ENSE000035876503010837330108432
ENSE000036795673011252330112568

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 97.67.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3244 / max 102.2041, expressed in 238 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
1570221.3244238

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
mucosa of transverse colonUBERON:000499197.67gold quality
lower esophagus mucosaUBERON:003583497.55gold quality
esophagus mucosaUBERON:000246994.37gold quality
esophagus squamous epitheliumUBERON:000692092.48gold quality
pharyngeal mucosaUBERON:000035592.20gold quality
epithelium of esophagusUBERON:000197692.18gold quality
oral cavityUBERON:000016789.93gold quality
ileal mucosaUBERON:000033189.92gold quality
transverse colonUBERON:000115789.90gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047389.53gold quality
squamous epitheliumUBERON:000691489.02gold quality
vaginaUBERON:000099688.93gold quality
ectocervixUBERON:001224987.84gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099187.83gold quality
esophagusUBERON:000104387.74gold quality
granulocyteCL:000009487.17gold quality
nasal cavity epitheliumUBERON:000538486.28gold quality
skin of legUBERON:000151186.12gold quality
rectumUBERON:000105286.00gold quality
gingival epitheliumUBERON:000194985.88gold quality
right hemisphere of cerebellumUBERON:001489085.75gold quality
small intestine Peyer’s patchUBERON:000345485.64gold quality
cerebellar hemisphereUBERON:000224585.38gold quality
right coronary arteryUBERON:000162585.34gold quality
cerebellar cortexUBERON:000212985.26gold quality
colonUBERON:000115585.14gold quality
gingivaUBERON:000182885.05gold quality
large intestineUBERON:000005985.02gold quality
body of uterusUBERON:000985384.85gold quality
right uterine tubeUBERON:000130284.83gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

ExperimentMarker?Max mean expression
E-ANND-3no2.53

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

  • Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake. (PMID:32430316)
  • Development of a selective fluorescence-based enzyme assay for glycerophosphodiesterase family members GDE4 and GDE7. (PMID:34673020)
  • GDE7 produces cyclic phosphatidic acid in the ER lumen functioning as a lysophospholipid mediator. (PMID:37193762)

Cross-species orthologs

4 orthologs

OrganismSymbolGene ID
danio_reriogdpd3bENSDARG00000006944
danio_reriogdpd3aENSDARG00000074466
mus_musculusGdpd3ENSMUSG00000030703
rattus_norvegicusGdpd3ENSRNOG00000019685

Paralogs (5): GDE1 (ENSG00000006007), GDPD2 (ENSG00000130055), GDPD1 (ENSG00000153982), GDPD5 (ENSG00000158555), GDPD4 (ENSG00000178795)

Protein

Protein identifiers

Lysophospholipase D GDPD3 — Q7L5L3 (reviewed: Q7L5L3)

Alternative names: Glycerophosphodiester phosphodiesterase 7, Glycerophosphodiester phosphodiesterase domain-containing protein 3

All UniProt accessions (3): Q7L5L3, H3BMN9, H3BPX3

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the corresponding amines. Shows a preference for 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), lysophosphatidylcholine (lyso-PC) and N-acylethanolamine lysophospholipids. Does not display glycerophosphodiester phosphodiesterase activity, since it cannot hydrolyze either glycerophosphoinositol or glycerophosphocholine.

Subcellular location. Membrane. Cytoplasm. Perinuclear region. Endoplasmic reticulum.

Tissue specificity. Widely expressed, with high level in kidney and ovary.

Activity regulation. Lysophospholipase D activity is stimulated by calcium. Loss of lysophospholipase D activity in presence of EDTA.

Similarity. Belongs to the glycerophosphoryl diester phosphodiesterase family.

Isoforms (2)

UniProt IDNamesCanonical?
Q7L5L3-21yes
Q7L5L3-12

RefSeq proteins (1): NP_077283* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR017946PLC-like_Pdiesterase_TIM-brlHomologous_superfamily
IPR030395GP_PDE_domDomain
IPR052271GDPD-RelatedFamily

Pfam: PF03009

Enzyme classification (BRENDA):

  • EC 3.1.4.39 — alkylglycerophosphoethanolamine phosphodiesterase (BRENDA: 14 organisms, 123 substrates, 265 inhibitors, 67 Km, 27 kcat entries)

Substrate kinetics (BRENDA)

32 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
LYSOPHOSPHATIDYLCHOLINE0.094–18
FS-30.0026–0.0194
LYSOPHOSPHATIDYLCHOLINE 16:00.066–0.1264
LYSOPHOSPHATIDYLCHOLINE 18:10.069–0.1264
4-NITROPHENYL-TMP0.7–5.63
LYSOPHOSPHATIDYLCHOLINE 18:00.089–0.273
1-LAUROYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOLINE1.9–2.32
1-LINOLEOYL-2-HYDROXY-SN-GLYCERO-SN-3-PHOSPHOCHO0.84–2.42
1-MYRISTOYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOLIN0.25–0.72
1-O-1’-(Z)-OCTADECENYL-2-HYDROXY-SN-GLYCERO-3-PH0.22–1.32
1-O-OCTADECYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOL0.16–0.312
1-OLEOYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOLINE0.28–0.562
1-PALMITOYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOLIN0.13–0.432
1-STEAROYL-2-HYDROXY-SN-GLYCERO-3-PHOSPHOCHOLINE0.2–0.32
1-ALKYL-SN-GLYCERO-3-PHOSPHOCHOLINE0.0971

Catalyzed reactions (Rhea), 7 shown:

  • 1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphate + choline + H(+) (RHEA:38975)
  • 1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = sn-glycerol 3-phosphocholine + hexadecanoate + H(+) (RHEA:40435)
  • 1-O-hexadecyl-sn-glycero-3-phosphocholine + H2O = 1-O-hexadecyl-sn-glycero-3-phosphate + choline + H(+) (RHEA:41143)
  • N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-1-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + H2O = N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H(+) (RHEA:45544)
  • N-hexadecanoyl-1-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + H2O = N-hexadecanoylethanolamine + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H(+) (RHEA:53168)
  • 1-O-(1Z-octadecenyl)-sn-glycero-3-phospho-N-hexadecanoyl-ethanolamine + H2O = 1-O-(1Z-octadecenyl)-sn-glycero-3-phosphate + N-hexadecanoylethanolamine + H(+) (RHEA:53184)
  • N,1-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + H2O = N-(9Z-octadecenoyl) ethanolamine + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H(+) (RHEA:56460)

UniProt features (11 total): topological domain 3, binding site 3, transmembrane region 2, chain 1, splice variant 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q7L5L3-F192.420.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 71; 73; 86

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

IDPathway
R-HSA-6814848Glycerophospholipid catabolism

MSigDB gene sets: 152 (showing top): ELVIDGE_HYPOXIA_DN, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, SASAI_TARGETS_OF_CXCR6_AND_PTCH1_UP, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1, GGGTGGRR_PAX4_03, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, chr16p11, HFH8_01, LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN, GOBP_ORGANOPHOSPHATE_CATABOLIC_PROCESS

GO Biological Process (5): phosphatidylcholine catabolic process (GO:0034638), glycerophospholipid catabolic process (GO:0046475), N-acylethanolamine metabolic process (GO:0070291), lipid metabolic process (GO:0006629), phospholipid metabolic process (GO:0006644)

GO Molecular Function (4): phosphatidylcholine lysophospholipase A1 activity (GO:0004622), phosphoric diester hydrolase activity (GO:0008081), metal ion binding (GO:0046872), hydrolase activity (GO:0016787)

GO Cellular Component (6): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

CategoryPathways
PI Metabolism1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
cytoplasm2
phosphatidylcholine metabolic process1
glycerophospholipid catabolic process1
glycerophospholipid metabolic process1
phospholipid catabolic process1
glycerolipid catabolic process1
primary alcohol metabolic process1
primary metabolic process1
lipid metabolic process1
organophosphate metabolic process1
lysophospholipase A1 activity1
phosphoric ester hydrolase activity1
cation binding1
catalytic activity1
endomembrane system1
intracellular membrane-bounded organelle1
organelle membrane1
nuclear outer membrane-endoplasmic reticulum membrane network1
endoplasmic reticulum subcompartment1
extracellular vesicle1
intracellular anatomical structure1

Protein interactions and networks

STRING

960 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
GDPD3ENPP2Q13822988
GDPD3ENPP3O14638921
GDPD3ENPP1P22413822
GDPD3LPAR1P78351750
GDPD3LPAR2Q9HBW0695
GDPD3LPAR6P43657691
GDPD3LPAR3Q9UBY5664
GDPD3LPAR4Q99677652
GDPD3YPEL3P61236617
GDPD3LPAR5Q9H1C0602
GDPD3HIRIP3Q9BW71591
GDPD3ASPHD1Q5U4P2572
GDPD3POU2F3Q9UKI9571
GDPD3NAPEPLDQ6IQ20528
GDPD3KCTD13Q8WZ19517

IntAct

40 interactions, top by confidence:

ABTypeScore
ANXA9PPLpsi-mi:“MI:0914”(association)0.660
PCGF6E2F6psi-mi:“MI:0914”(association)0.640
NPPAA2ML1psi-mi:“MI:0914”(association)0.530
TBC1D22BA2ML1psi-mi:“MI:0914”(association)0.530
DNAAF19KLK10psi-mi:“MI:0914”(association)0.530
ZIC1CTSVpsi-mi:“MI:0914”(association)0.530
AIREALOX12Bpsi-mi:“MI:0914”(association)0.530
CUL2ANXA2P2psi-mi:“MI:0914”(association)0.350
DYRK3EIF3Fpsi-mi:“MI:0914”(association)0.350
MAP3K6TGM1psi-mi:“MI:0914”(association)0.350
PRKAG1TGM1psi-mi:“MI:0914”(association)0.350
FASTKTGM1psi-mi:“MI:0914”(association)0.350
CDKL3psi-mi:“MI:0914”(association)0.350
STX17A2ML1psi-mi:“MI:0914”(association)0.350
PI4KAP1A2ML1psi-mi:“MI:0914”(association)0.350
ST6GALNAC6A2ML1psi-mi:“MI:0914”(association)0.350
GABPAA2ML1psi-mi:“MI:0914”(association)0.350
RIPPLY3A2ML1psi-mi:“MI:0914”(association)0.350
MBD4A2ML1psi-mi:“MI:0914”(association)0.350
ST7A2ML1psi-mi:“MI:0914”(association)0.350
PTDSS1IGLL5psi-mi:“MI:0914”(association)0.350
CCR1UBA6psi-mi:“MI:0914”(association)0.350
ERCC3A2ML1psi-mi:“MI:0914”(association)0.350
SH2D3AA2ML1psi-mi:“MI:0914”(association)0.350
PINK1A2ML1psi-mi:“MI:0914”(association)0.350
PCP4A2ML1psi-mi:“MI:0914”(association)0.350
UPK1AA2ML1psi-mi:“MI:0914”(association)0.350
SARAFA2ML1psi-mi:“MI:0914”(association)0.350
NT5C1AA2ML1psi-mi:“MI:0914”(association)0.350
ZC3HC1SULT2B1psi-mi:“MI:0914”(association)0.350

BioGRID (43): GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS), GDPD3 (Affinity Capture-MS)

ESM2 similar proteins: A0A193KX02, A0A397HK53, A1Y9I9, A4IG53, A5WWC6, B6CZ46, B6CZ56, B6CZ62, B8NR70, L0TAD5, O42898, P37059, P55205, P58781, P86243, Q0IIS3, Q0P464, Q28C60, Q28DI5, Q2KHV5, Q2VQV9, Q32LS6, Q3V1F8, Q4V339, Q5JTY5, Q5RIA9, Q5XI69, Q5XI79, Q66KL0, Q68EZ3, Q6DCK1, Q6GQ37, Q6PE54, Q6Q2C2, Q6TL19, Q7L592, Q7L5L3, Q8IUF1, Q8IX18, Q8NKC1

Diamond homologs: A0A8F4N283, O07592, O30405, P09394, P37965, P47535, P54527, P75367, P9WLF0, P9WLF1, Q06282, Q08959, Q3T0T0, Q3TT99, Q640M6, Q6W3E5, Q7L5L3, Q8RB32, Q95JR7, Q99LY2, Q9C907, Q9ESM6, Q9HCC8, Q9JL56, Q9NZC3, Q9SD81, O14169, P10908, P9WMU2, P9WMU3, Q8N9F7, Q8WTR4, Q9CRY7, Q9JL55, P47625, Q3KTM2, Q0VGK4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic1
Likely pathogenic1
Uncertain significance44
Likely benign6
Benign1

Top pathogenic / likely-pathogenic (2)

Variant IDHGVSClassification
983192GRCh37/hg19 16p11.2(chr16:29592797-30190593)x3Pathogenic
523255GRCh37/hg19 16p11.2(chr16:29656684-30197341)Likely pathogenic

SpliceAI

1529 predictions. Top by Δscore:

VariantEffectΔscore
16:30111382:TGGTA:Tdonor_loss1.0000
16:30111383:GGTAC:Gdonor_loss1.0000
16:30111384:GTAC:Gdonor_loss1.0000
16:30111385:TACCT:Tdonor_loss1.0000
16:30111386:ACCTG:Adonor_loss1.0000
16:30111425:T:TAdonor_gain1.0000
16:30111517:GGGTT:Gacceptor_gain1.0000
16:30111518:GGTT:Gacceptor_gain1.0000
16:30111519:GTT:Gacceptor_gain1.0000
16:30111520:TT:Tacceptor_gain1.0000
16:30111520:TTCTG:Tacceptor_loss1.0000
16:30111521:TC:Tacceptor_loss1.0000
16:30111522:C:CAacceptor_loss1.0000
16:30111522:C:CCacceptor_gain1.0000
16:30111523:T:Aacceptor_loss1.0000
16:30112130:A:ACdonor_gain1.0000
16:30112130:ACGG:Adonor_gain1.0000
16:30112131:C:CAdonor_gain1.0000
16:30112131:CGG:Cdonor_gain1.0000
16:30112131:CGGC:Cdonor_gain1.0000
16:30112131:CGGCA:Cdonor_gain1.0000
16:30112149:TCATG:Tdonor_gain1.0000
16:30112218:CTAT:Cacceptor_gain1.0000
16:30112309:A:ACdonor_gain1.0000
16:30112310:C:CCdonor_gain1.0000
16:30112329:T:TAdonor_gain1.0000
16:30112330:C:Adonor_gain1.0000
16:30112517:TCTCA:Tdonor_loss1.0000
16:30112518:CTCAC:Cdonor_loss1.0000
16:30112519:TCACC:Tdonor_loss1.0000

AlphaMissense

2067 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
16:30112176:A:GW177R0.986
16:30112176:A:TW177R0.986
16:30113345:C:GR45P0.979
16:30104936:G:TT298K0.978
16:30108223:C:GR270P0.978
16:30112193:C:GR171P0.977
16:30113046:T:AE53V0.973
16:30113349:G:CH44D0.970
16:30112194:G:TR171S0.969
16:30112754:A:CC74W0.968
16:30112756:A:GC74R0.968
16:30104934:C:GD299H0.967
16:30104942:A:TV296D0.967
16:30112530:G:CF119L0.965
16:30112530:G:TF119L0.965
16:30112532:A:GF119L0.965
16:30104932:A:CD299E0.962
16:30104932:A:TD299E0.962
16:30104936:G:CT298R0.962
16:30112143:A:GC188R0.962
16:30112723:A:GS85P0.962
16:30104933:T:AD299V0.960
16:30104966:G:TA288D0.960
16:30113040:G:AT55I0.960
16:30112746:G:AT77I0.959
16:30112702:G:TR92S0.956
16:30112333:T:AK152N0.955
16:30112333:T:GK152N0.955
16:30112716:T:AD87V0.955
16:30104933:T:GD299A0.954

dbSNP variants (sampled 300 via entrez): RS1000228969 (16:30107161 C>T), RS1000632261 (16:30111910 G>A), RS1000703831 (16:30110378 C>A), RS1000737377 (16:30111692 G>A,C), RS1001796639 (16:30111077 T>C), RS1002003921 (16:30105991 A>G), RS1002248461 (16:30112198 A>G), RS1002521758 (16:30105794 C>T), RS1002689126 (16:30108832 A>T), RS1002848580 (16:30113546 A>G), RS1003316506 (16:30109581 T>C,G), RS1003532842 (16:30104475 G>A), RS1003998795 (16:30113964 T>G), RS1004294823 (16:30114227 G>A), RS1004683414 (16:30114078 G>A,T)

Disease associations

OMIM: gene MIM:616318 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (1): Non-syndromic bicoronal craniosynostosis (Orphanet:35099)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

StudyTraitp-value
GCST002539_82Schizophrenia5.000000e-11
GCST004521_236Autism spectrum disorder or schizophrenia4.000000e-10
GCST006803_23Schizophrenia6.000000e-13
GCST007293_15Body fat distribution (arm fat ratio)6.000000e-06
GCST007293_81Body fat distribution (arm fat ratio)4.000000e-08
GCST010703_269Brain morphology (MOSTest)4.000000e-13

EFO canonical traits (2, from GWAS)

EFO IDTrait name
EFO:0004341body fat distribution
EFO:0004346neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Estradiolaffects cotreatment, decreases expression4
Amitriptylineincreases expression3
Tamoxifenincreases expression3
Amiodaroneincreases expression2
trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochlorideincreases expression2
Chlorpromazineincreases expression2
Clozapineincreases expression2
Fluoxetineincreases expression2
Imipramineincreases expression2
Ketoconazoleincreases expression2
Perhexilineincreases expression2
Smokedecreases expression2
Valproic Acidincreases expression, increases methylation2
Sertralineincreases expression2
Particulate Matterincreases expression2
aristolochic acid Iincreases expression1
OTX015decreases expression1
mivebresibdecreases expression1
triphenyl phosphateaffects expression1
sodium arsenateincreases abundance, decreases expression1
testosterone undecanoateincreases expression1
perfluorooctanoic acidaffects cotreatment, increases expression1
zinc chromateincreases abundance, increases expression1
2,3-bis(3’-hydroxybenzyl)butyrolactoneaffects cotreatment, decreases expression1
hydroquinoneincreases expression1
chromium hexavalent ionincreases abundance, increases expression1
chlorcyclizineincreases expression1
CGP 52608affects binding, increases reaction1
K 7174decreases expression1
bisphenol Sdecreases expression1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 75

This page pulls from 75 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot